Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (681-690 of 1,211) with videos related to

Pageof 122
Sort By:
JACC. Heart Failure|August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart FailureJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American College of Cardiology|December 17, 2021
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic CardiomyopathySheila M Hegde, Steven J Lester, Scott D Solomon, et al.
JACC. Heart Failure|February 11, 2019
Income Inequality and Outcomes in Heart Failure: A Global Between-Country AnalysisPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
The Journal of Infection|May 25, 2024
The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trialsKristoffer Grundtvig Skaarup, Mats Christian Højbjerg Lassen, Daniel Modin, et al.
Circulation|December 28, 2018
Refining Prediction of Atrial Fibrillation-Related Stroke Using the P<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc ScoreAnkit Maheshwari, Faye L Norby, Nicholas S Roetker, et al.
European Journal of Heart Failure|February 13, 2018
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, et al.
European Journal of Heart Failure|February 19, 2024
Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF studyMasatoshi Minamisawa, Riccardo M Inciardi, Brian Claggett, et al.
Journal of the American College of Cardiology|December 7, 2019
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection FractionAmil M Shah, Maja Cikes, Narayana Prasad, et al.
Pageof 122

Showing results (681-690 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart FailureJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American College of Cardiology|December 17, 2021
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic CardiomyopathySheila M Hegde, Steven J Lester, Scott D Solomon, et al.
JACC. Heart Failure|February 11, 2019
Income Inequality and Outcomes in Heart Failure: A Global Between-Country AnalysisPooja Dewan, Rasmus Rørth, Pardeep S Jhund, et al.
JAMA Cardiology|July 28, 2021
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical TrialKieran F Docherty, Pardeep S Jhund, Brian Claggett, et al.
Journal of the American College of Cardiology|March 27, 2024
Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
The Journal of Infection|May 25, 2024
The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trialsKristoffer Grundtvig Skaarup, Mats Christian Højbjerg Lassen, Daniel Modin, et al.
Circulation|December 28, 2018
Refining Prediction of Atrial Fibrillation-Related Stroke Using the P<sub>2</sub>-CHA<sub>2</sub>DS<sub>2</sub>-VASc ScoreAnkit Maheshwari, Faye L Norby, Nicholas S Roetker, et al.
European Journal of Heart Failure|February 13, 2018
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Ulrik M Mogensen, Jianjian Gong, Pardeep S Jhund, et al.
European Journal of Heart Failure|February 19, 2024
Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF studyMasatoshi Minamisawa, Riccardo M Inciardi, Brian Claggett, et al.
Journal of the American College of Cardiology|December 7, 2019
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection FractionAmil M Shah, Maja Cikes, Narayana Prasad, et al.
Pageof 122